SCHEDULE: Faraday Future Invests in Qualigen, Pivots to Crypto

Faraday Future Intelligent Electric Inc. has acquired an 8.0% stake in Qualigen Therapeutics, Inc., initiating a strategic pivot towards cryptocurrency and significant governance changes.

Summary

• Faraday Future Intelligent Electric Inc. (FFIE) has acquired 248,722 shares of Qualigen Therapeutics, Inc. (QLGN) common stock, representing an 8.0% beneficial ownership.
• The acquisition was part of a private placement offering, with shares purchased at $2.246 per common share and/or Series B preferred stock at $1,000 per share, funded by FFIE's working capital.
• FFIE has committed to investing a minimum of $30 million in the private placement.
• Qualigen Therapeutics will adopt a new Treasury Reserve Policy, making cryptocurrencies the primary treasury reserve asset, subject to market conditions and oversight by a new Co-Chief Executive Officer.
• Significant corporate governance changes are planned, including a reduction in the Board size to five, then an expansion to seven members, with FFIE designating up to four directors, including the Board Chairperson.
• Jiawei Wang (or FFIE designee) will be appointed Co-Chief Executive Officer, responsible for all business operations except medical-related business, including crypto-related ventures, with sole access to crypto accounts.
• Koti Meka (or FFIE designee) will be appointed Chief Financial Officer, and Mr. YT Jia will be appointed Chief Advisor for strategic advisory services.
• Qualigen will reimburse FFIE up to $500,000 for legal, accounting, and professional fees incurred in connection with the private placement.
• Stockholder approval is required for the governance changes and for the issuance of conversion shares exceeding 19.99% of outstanding shares, with QLGN committing to seek this approval within 40-70 days.
• FFIE has the right to participate in future Qualigen financings proportionate to its beneficial ownership.
• Qualigen will file a Shelf Registration Statement on Form S-3 within 45 days to register the resale of the acquired securities, granting FFIE demand and piggyback registration rights.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to a significant capital injection and a bold strategic pivot with strong backing from a new strategic investor. However, the inherent risks of entering a new, volatile industry like cryptocurrency, the need for stockholder approval, and the substantial shift in corporate control temper the overall positive outlook.

Positives

• Secured a significant capital injection of at least $30 million from Faraday Future Intelligent Electric Inc., providing crucial funding for Qualigen's operations and new strategic direction.
• Gained a strategic partner with expertise in technology and potentially new market insights, as Faraday Future is an intelligent electric mobility ecosystem company.
• Initiated a strategic pivot into the cryptocurrency sector, potentially opening new growth avenues and diversifying Qualigen's business beyond its traditional medical focus.
• Strengthened corporate governance and management with the appointment of FFIE-designated directors to the Board and key executive roles (Co-CEO, CFO), bringing new leadership and oversight.
• Established a clear Treasury Reserve Policy prioritizing cryptocurrencies, signaling a committed shift in asset management strategy.

Negatives

• The strategic pivot to a cryptocurrency-related business represents a significant departure from Qualigen's historical medical focus, introducing substantial new operational and market risks.
• The blank 'minimum aggregate Purchase Price' in the Subscription Agreement for closing indicates a lack of full disclosure on the total capital raise target, which could be a concern for transparency.
• The substantial control granted to Faraday Future, including board majority potential and exclusive control over new business operations and crypto accounts, could dilute the influence of existing shareholders and management.
• The requirement for stockholder approval for key governance changes and conversion shares exceeding 19.99% introduces uncertainty and potential delays in implementing the new strategy.
• The investment amount of $30 million, while significant, is being allocated across general corporate purposes, debt satisfaction, and the new crypto business, which may spread resources thinly across diverse objectives.

Risks

• The new cryptocurrency-related business introduces significant market volatility and regulatory risks inherent to digital assets, which are distinct from Qualigen's traditional biotech operations.
• Reliance on Faraday Future's expertise and commitment for the success of the new crypto strategy, as well as for future financing, creates dependency.
• Potential for conflicts of interest between the new FFIE-appointed management and directors and the interests of existing Qualigen shareholders, particularly concerning the allocation of resources between the medical and crypto businesses.
• Failure to obtain timely stockholder approval for the proposed governance changes and share issuances could delay or derail the strategic pivot and new management structure.
• The ability to effectively integrate new management and a completely different business focus (crypto) into an existing biotech company structure poses operational and cultural challenges.

Future Outlook

Qualigen Therapeutics is embarking on a significant strategic shift, intending to establish a new cryptocurrency-related business and make cryptocurrencies its primary treasury reserve asset. This pivot will be overseen by a new Co-Chief Executive Officer designated by Faraday Future, who will have exclusive control over the implementation of the Treasury Reserve Policy and all new business affairs. The company also plans to expand its equity incentive pool and amend its 2020 Stock Equity Incentive Plan, subject to stockholder approval. Faraday Future retains rights to participate in future Qualigen financings, indicating a long-term strategic partnership.

Management Comments

• The Reporting Person (Faraday Future) acquired the shares for general investment purposes and may, from time to time, acquire additional shares, dispose of securities, or engage in discussions concerning further investments.
• The Reporting Person intends to review its investment in the Issuer on a continuing basis and may decide at any time to increase the size of its investment.

Industry Context

This announcement signals a notable strategic pivot for Qualigen Therapeutics, a company traditionally focused on medical therapeutics, into the burgeoning and volatile cryptocurrency sector. This move aligns with a broader trend of companies exploring digital assets for treasury management and new business ventures, though it is less common for a biotech firm to make such a direct and significant shift. The involvement of Faraday Future, an intelligent electric mobility ecosystem company, suggests a cross-industry strategic alliance, potentially leveraging technology and investment expertise from the EV sector into digital assets and a new direction for Qualigen.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or results for direct assessment against industry standards. The strategic pivot to cryptocurrency for a biotech company is an unusual move, making direct comparisons difficult.
• The adoption of cryptocurrencies as a primary treasury reserve asset, while gaining traction among some tech-forward companies, is not a standard practice for traditional biotech firms, indicating a high-risk, high-reward strategy.

Management Changes

Corporate Governance

Legal Proceedings

• Faraday Future Intelligent Electric Inc. has not been convicted in a criminal proceeding (excluding traffic violations) nor been a party to a civil proceeding resulting in a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws, during the last five years.
• Qualigen Therapeutics, Inc. states there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or threatened against or affecting the Issuer or any Significant Subsidiary that would have a Material Adverse Effect, except as set forth on Schedule 4(bb) (which was not provided in the filing excerpt).

Related Party Transactions

• No officers or directors of Qualigen Therapeutics or any Significant Subsidiary, nor any employees, are presently a party to any transaction with Qualigen or any Significant Subsidiary (other than for services as employees, officers, and directors) in excess of $120,000, except as set forth in the SEC Documents or for standard compensation (salary, consulting fees, expense reimbursement, employee benefits including stock options).

Stakeholder Impact

• Shareholders: Potential for significant dilution from the private placement and future share issuances. The strategic pivot to cryptocurrency introduces a new risk/reward profile, potentially attracting new investors but alienating traditional biotech investors. Governance changes will shift control towards Faraday Future.
• Employees: New management (Co-CEO, CFO, Chief Advisor) designated by Faraday Future may lead to changes in corporate culture, priorities, and potentially staffing, especially concerning the new crypto business.
• Customers: Existing customers of Qualigen's medical-related business may see continued management by the current CEO, but the overall company focus and resource allocation may shift, potentially impacting future product development or service quality in the medical sector. New customers may emerge for the crypto business.
• Creditors: The capital raise provides additional liquidity, which could improve the company's ability to meet existing debt obligations. However, the strategic pivot to a new, potentially volatile business area introduces new financial risks.

Next Steps

• Qualigen Therapeutics to obtain stockholder approval for governance changes and share issuances within 40-70 days following the agreement date.
• Qualigen to file a Shelf Registration Statement on Form S-3 within 45 days to register the resale of the acquired securities.
• Qualigen to appoint Jiawei Wang (or FFIE designee) as Co-Chief Executive Officer and Koti Meka (or FFIE designee) as Chief Financial Officer upon closing.
• Qualigen to negotiate and enter into an advisory agreement with Mr. YT Jia as Chief Advisor within 30 days of closing.
• Qualigen to adopt a Treasury Reserve Policy, making cryptocurrencies a primary treasury reserve asset, effective upon closing.
• Qualigen and Faraday Future to negotiate a form of exchange agreement for holders of Qualigen Series A-2 and A-3 preferred stock within 60 days of closing.

Key Dates

Recommendation

This filing presents a transformative event for Qualigen Therapeutics, marked by a substantial capital infusion and a dramatic strategic pivot into the cryptocurrency sector, heavily influenced by a new strategic investor, Faraday Future. While the capital raise and new strategic direction offer potential for significant upside, they also introduce considerable risk and uncertainty. The company is moving away from its core biotech business into a highly volatile and regulated industry, with new management taking significant control. For a seasoned investor, this represents a speculative opportunity. A 'hold' recommendation is appropriate for existing shareholders to observe the execution of this new strategy and the integration of new management, while potential new investors should approach with caution, recognizing the high-risk, high-reward nature of this pivot. Further analysis of the new crypto business model, regulatory landscape, and management's execution capabilities will be crucial.

Keywords

Qualigen Therapeutics, Faraday Future, Private Placement, Strategic Investment, Cryptocurrency, Corporate Governance, Board Changes, Management Changes, SEC Filing, Schedule 13D, Equity Investment, Biotech, Digital Assets